Active, not recruitingNCT05013190

A Study of NINLARO® in Chinese Adults With Multiple Myeloma

Studying Multiple myeloma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Takeda
Principal Investigator: Study Director
Takeda
Intervention: No intervention(other)
Enrollment: 72 enrolled
Eligibility: 18 years · All sexes
Timeline: 2021 – 2026

Study locations (12)

Anhui Cancer Hospital, Hefei, Anhui, China
Beijing Chao-Yang Hospital,Capital Medical University, Beijing, Beijing Municipality, China
Beijing Jishuitan Hospital, Beijing, Beijing Municipality, China
Henan Province People Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Zhenzhou University, Zhengzhou, Henan, China
Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China
Qingdao Municipal Hospital, Qingdao, Qingdao, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05013190 on ClinicalTrials.gov

Other trials for Multiple myeloma

Additional recruiting or active studies for the same condition.

See all trials for Multiple myeloma →

← Back to all trials